Li Ying-Hong, Fu Hai-Gen, Su Feng, Gao Li-Mei, Tang Sheng, Bi Chong-Wen, Li Yu-Huan, Wang Yan-Xiang, Song Dan-Qing
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Chem Cent J. 2013 Jul 10;7(1):117. doi: 10.1186/1752-153X-7-117.
The emergence of multi-drug resistant tuberculosis (MDR-TB) has heightened the need for new chemical classes and innovative strategies to tackle TB infections. It is urgent to discover new classes of molecules without cross-resistance with currently used antimycobacterial drugs.
Eighteen new 8-substituted protoberberine derivatives were synthesized and evaluated for their anti-mycobacterial activities against Mycobacterium tuberculosis (M. tuberculosis) strain H37Rv. Among them, compound 7g was the most effective antitubercular agent with minimum inhibitory concentration (MIC) of 0.5 μg/mL. Moreover, it also afforded a potent antitubercular effect against clinically isolated MDR strains of M. tuberculosis with MICs ranging from 0.25 to 1.0 μg/mL, suggesting a novel mode of action.
The structure-activity relationship (SAR) analysis revealed that introduction of a substituent at the 8-position in pseudoprotoberberine, especially an n-decyl, could significantly enhance the anti-TB activity. We consider 8-n-decylberberines to be a novel family of anti-tubercular agents with an advantage of inhibiting MDR strains of M. tuberculosis.
多重耐药结核病(MDR-TB)的出现增加了对新化学类别和创新策略来应对结核病感染的需求。迫切需要发现与目前使用的抗分枝杆菌药物无交叉耐药性的新型分子类别。
合成了18种新的8-取代原小檗碱衍生物,并评估了它们对结核分枝杆菌H37Rv菌株的抗分枝杆菌活性。其中,化合物7g是最有效的抗结核药物,最低抑菌浓度(MIC)为0.5μg/mL。此外,它对临床分离的结核分枝杆菌MDR菌株也具有强效抗结核作用,MIC范围为0.25至1.0μg/mL,提示其作用模式新颖。
构效关系(SAR)分析表明,在假原小檗碱的8位引入取代基,特别是正癸基,可显著增强抗结核活性。我们认为8-正癸基小檗碱是一类新型抗结核药物,具有抑制结核分枝杆菌MDR菌株的优势。